Dapagliflozin effective in treating type 1 diabetes
Type 1 diabetes is a worrying condition as ones immune system destroys insulin-making cells in the pancreas. Recent data published in PLOS One supports the preventive and protective role of SGLT2 inhibitors in cardiovascular disease (CVD) associated with type 1 diabetes.
The study provides experimental data for SGLT2i dapagliflozin's (DAPA) cardioprotective effect in T1D. Results showed that DAPA prevents cardiac inflammation, fibrosis, and intimal thickening. This suggests that SGLT2i may provide a novel therapeutic opportunity for hindering the development of CVD in type 1 diabetes, thereby improving the outcomes.
For more information check out the full story on the link below:
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)